Impact of drug therapy and surgery on quality of life in crohn's disease: A systematic review

Inflammatory Bowel Diseases

Volumn 21, Issue 5, 2015, Pages 1187-1194

  Wright, Emily K ^a   Kamm, Michael A ^a,b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Crohn's disease; immunomodulators; intestinal resection; postoperative; quality of life

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; BUDESONIDE; CORTICOSTEROID; GLUCOCORTICOID; MESALAZINE; NATALIZUMAB; VEDOLIZUMAB;

CLINICAL TRIAL (TOPIC); COPING BEHAVIOR; CROHN DISEASE; DISEASE ACTIVITY; EMOTION; GENDER; HUMAN; IMMUNOMODULATION; INTESTINE RESECTION; MENTAL DISEASE; PERCEPTION; PERSONALITY; PHENOTYPE; PHYSICAL ACTIVITY; PRIORITY JOURNAL; QUALITY OF LIFE; RECURRENT DISEASE; REMISSION; REVIEW; SOCIAL SUPPORT; SYSTEMATIC REVIEW; WELLBEING; MULTIMODALITY CANCER THERAPY; PROGNOSIS; SEVERITY OF ILLNESS INDEX;

COMBINED MODALITY THERAPY; CROHN DISEASE; HUMANS; PROGNOSIS; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX;

EID: 84929076272     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0000000000000271     Document Type: Review

References (131)

1. Williet N, Sandborn WJ, Peyrin-Biroulet L. Patient-reported outcomes as primary end points in clinical trials of inflammatory bowel disease. Clin Gastroenterol Hepatol. 2014;12:1246 e6-1256 e6.
2. Schipper H. Guidelines and caveats for quality of life measurement in clinical practice and research. Oncology. 1990;4:51-57.
3. Peyrin-Biroulet L, Cieza A, Sandborn WJ, et al. Disability in inflammatory bowel diseases: developing ICF Core Sets for patients with inflammatory bowel diseases based on the international classification of functioning, disability, and health. Inflamm Bowel Dis. 2010;16:15-22.
4. Peyrin-Biroulet L, Loftus EV Jr, Colombel JF, et al. Long-Term complications, extraintestinal manifestations, and mortality in adult Crohn's disease in population-based cohorts. Inflamm Bowel Dis. 2011;17:471-478.
5. Peyrin-Biroulet L, Cieza A, Sandborn WJ, et al. Development of the first disability index for inflammatory bowel disease based on the international classification of functioning, disability and health. Gut. 2012;61: 241-247.
6. Allen PB, Kamm MA, Peyrin-Biroulet L, et al. Development and validation of a patient-reported disability measurement tool for patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2013;37:438-444.
7. Ghosh S, Mitchell R. Impact of inflammatory bowel disease on quality of life: results of the European Federation of Crohn's and Ulcerative Colitis Associations (EFCCA) patient survey. J Crohns Colitis. 2007;1:10-20.
8. Schirbel A, Reichert A, Roll S, et al. Impact of pain on health-related quality of life in patients with inflammatory bowel disease. World J Gastroenterol. 2010;16:3168-3177.
9. Nagy B, Laczkone Majer R. Specific quality of life factors in patients with inflammatory bowel disease [in Hungarian]. Orv Hetil. 2012;153: 1511-1519.
10. Lesage AC, Hagege H, Tucat G, et al. Results of a national survey on quality of life in inflammatory bowel diseases. Clin Res Hepatol Gastroenterol. 2011;35:117-124.
11. Lichtenstein GR, Yan S, Bala M, et al. Remission in patients with Crohn's disease is associated with improvement in employment and quality of life and a decrease in hospitalizations and surgeries. Am J Gastroenterol. 2004;99:91-96.
12. Larsson K, Loof L, Ronnblom A, et al. Quality of life for patients with exacerbation in inflammatory bowel disease and how they cope with disease activity. J Psychosom Res. 2008;64:139-148.
13. Iglesias M, Vazquez I, Barreiro-de Acosta M, et al. Health related quality of life in patients with Cohn's disease in remission. Rev Esp Enferm Dig. 2010;102:624-630.
14. Drossman DA, Patrick DL, Mitchell CM, et al. Health-related quality of life in inflammatory bowel disease. Functional status and patient worries and concerns. Dig Dis Sci. 1989;34:1379-1386.
15. Casellas F, Barreiro de Acosta M, Iglesias M, et al. Mucosal healing restores normal health and quality of life in patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol. 2012;24:762-769.
16. Calvet X, Gallardo O, Coronas R, et al. Remission on thiopurinic immunomodulators normalizes quality of life and psychological status in patients with Crohn's disease. Inflamm Bowel Dis. 2006;12:692-696.
17. Vogelaar L, Spijker AV, van der Woude CJ. The impact of biologics on health-related quality of life in patients with inflammatory bowel disease. Clin Exp Gastroenterol. 2009;2:101-109.
18. Bastida G, Nos P, Aguas M, et al. The effects of thiopurine therapy on health-related quality of life in Inflammatory Bowel Disease patients. BMC Gastroenterol. 2010;10:26.
19. Feagan BG, Rochon J, Fedorak RN, et al. Methotrexate for the treatment of Crohn's disease. The North American Crohn's study group investigators. N Engl J Med. 1995;332:292-297.
20. Louis E, Lofberg R, Reinisch W, et al. Adalimumab improves patientreported outcomes and reduces indirect costs in patients with moderate to severe Crohn's disease: results from the CARE trial. J Crohns Colitis. 2013;7:34-43.
21. Panaccione R, Loftus EV Jr, Binion D, et al. Efficacy and safety of adalimumab in Canadian patients with moderate to severe Crohn's disease: results of the Adalimumab in Canadian SubjeCts with ModErate to Severe Crohn's DiseaSe (ACCESS) trial. Can J Gastroenterol. 2011;25:419-425.
22. Cross RK, Lapshin O, Finkelstein J. Patient subjective assessment of drug side effects in inflammatory bowel disease. J Clin Gastroenterol. 2008;42:244-251.
23. Thirlby RC, Land JC, Fenster LF, et al. Effect of surgery on healthrelated quality of life in patients with inflammatory bowel disease: a prospective study. Arch Surg. 1998;133:826-832.
24. Lesperance K, Martin MJ, Lehmann R, et al. National trends and outcomes for the surgical therapy of ileocolonic Crohn's disease: a population-based analysis of laparoscopic vs. open approaches. J Gastrointest Surg. 2009; 13:1251-1259.
25. Delaney CP, Kiran RP, Senagore AJ, et al. Quality of life improves within 30 days of surgery for Crohn's disease. J Am Coll Surg. 2003; 196:714-721.
26. Tillinger W, Mittermaier C, Lochs H, et al. Health-related quality of life in patients with Crohn's disease: influence of surgical operation-A prospective trial. Dig Dis Sci. 1999;44:932-938.
27. Scarpa M, Ruffolo C, D'Inca R, et al. Health-related quality of life after ileocolonic resection for Crohn's disease: long-Term results. Inflamm Bowel Dis. 2007;13:462-469.
28. Thirlby RC, Sobrino MA, Randall JB. The long-Term benefit of surgery on health-related quality of life in patients with inflammatory bowel disease. Arch Surg. 2001;136:521-527.
29. Thaler K, Dinnewitzer A, Oberwalder M, et al. Assessment of long-Term quality of life after laparoscopic and open surgery for Crohn's disease. Colorectal Dis. 2005;7:375-381.
30. Bernklev T, Jahnsen J, Aadland E, et al. Health-related quality of life in patients with inflammatory bowel disease five years after the initial diagnosis. Scand J Gastroenterol. 2004;39:365-373.
31. Hoivik ML, Bernklev T, Solberg IC, et al. Patients with Crohn's disease experience reduced general health and vitality in the chronic stage: tenyear results from the IBSEN study. J Crohns Colitis. 2012;6:441-453.
32. Canavan C, Abrams KR, Hawthorne B, et al. Long-Term prognosis in Crohn's disease: factors that affect quality of life. Aliment Pharmacol Ther. 2006;23:377-385.
33. Love JR, Irvine EJ, Fedorak RN. Quality of life in inflammatory bowel disease. J Clin Gastroenterol. 1992;14:15-19.
34. Jaghult S, Saboonchi F, Johansson UB, et al. Identifying predictors of low health-related quality of life among patients with inflammatory bowel disease: comparison between Crohn's disease and ulcerative colitis with disease duration. J Clin Nurs. 2011;20:1578-1587.
35. Stjernman H, Tysk C, Almer S, et al. Unfavourable outcome for women in a study of health-related quality of life, social factors and work disability in Crohn's disease. Eur J Gastroenterol Hepatol. 2011;23:671-679.
36. Wilson BS, L S, Vermeire S, et al. The true impact of IBD: a European Crohn's and ulcerative colitis patient life. IMPACT Surv 2010-2011.
37. Binder V, Hendriksen C, Kreiner S. Prognosis in Crohn's disease-based on results from a regional patient group from the county of Copenhagen. Gut. 1985;26:146-150.
38. Feagan BG, Bala M, Yan S, et al. Unemployment and disability in patients with moderately to severely active Crohn's disease. J Clin Gastroenterol. 2005;39:390-395.
39. Bernklev T, Jahnsen J, Henriksen M, et al. Relationship between sick leave, unemployment, disability, and health-related quality of life in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2006; 12:402-412.
40. Casellas F, Robles V, Borruel N, et al. Restoration of quality of life of patients with inflammatory bowel disease after one year with antiTNFalpha treatment. J Crohns Colitis. 2012;6:881-886.
41. Colombel JF, Rutgeerts PJ, Sandborn WJ, et al. Adalimumab induces deep remission in patients with Crohn's disease. Clin Gastroenterol Hepatol. 2013.
42. Feagan BG, Sandborn WJ, Hass S, et al. Health-related quality of life during natalizumab maintenance therapy for Crohn's disease. Am J Gastroenterol. 2007;102:2737-2746.
43. Moradkhani A, Beckman LJ, Tabibian JH. Health-related quality of life in inflammatory bowel disease: psychosocial, clinical, socioeconomic, and demographic predictors. J Crohns Colitis. 2013;7:467-473.
44. Casellas F, Lopez-Vivancos J, Casado A, et al. Factors affecting health related quality of life of patients with inflammatory bowel disease. Qual Life Res. 2002;11:775-781.
45. Rubin GP, Hungin AP, Chinn DJ, et al. Quality of life in patients with established inflammatory bowel disease: a UK general practice survey. Aliment Pharmacol Ther. 2004;19:529-535.
46. Hauser G, Tkalcic M, Stimac D, et al. Gender related differences in quality of life and affective status in patients with inflammatory bowel disease. Coll Antropol. 2011;35(suppl 2):203-207.
47. Moreno-Jimenez B, Lopez Blanco B, Rodriguez-Munoz A, et al. The influence of personality factors on health-related quality of life of patients with inflammatory bowel disease. J Psychosom Res. 2007; 62:39-46.
48. Blondel-Kucharski F, Chircop C, Marquis P, et al. Health-related quality of life in Crohn's disease: a prospective longitudinal study in 231 patients. Am J Gastroenterol. 2001;96:2915-2920.
49. Russel MG, Nieman FH, Bergers JM, et al. Cigarette smoking and quality of life in patients with inflammatory bowel disease. South Limburg IBD Study Group. Eur J Gastroenterol Hepatol. 1996;8:1075-1081.
50. Joyce MR, Hannaway CD, Strong SA, et al. Impact of smoking on disease phenotype and postoperative outcomes for Crohn's disease patients undergoing surgery. Langenbecks Arch Surg. 2013;398:39-45.
51. Crumbock SC, Loeb SJ, Fick DM. Physical activity, stress, disease activity, and quality of life in adults with Crohn disease. Gastroenterol Nurs. 2009;32:188-195.
52. Ng V, Millard W, Lebrun C, et al. Low-intensity exercise improves quality of life in patients with Crohn's disease. Clin J Sport Med. 2007;17:384-388.
53. Zhou Y, Ren W, Irvine EJ, et al. Assessing health-related quality of life in patients with inflammatory bowel disease in Zhejiang, China. J Clin Nurs. 2010;19:79-88.
54. Romberg-Camps MJ, Bol Y, Dagnelie PC, et al. Fatigue and healthrelated quality of life in inflammatory bowel disease: results from a population-based study in the Netherlands: the IBD-South Limburg cohort. Inflamm Bowel Dis. 2010;16:2137-2147.
55. Graff LA, Walker JR, Lix L, et al. The relationship of inflammatory bowel disease type and activity to psychological functioning and quality of life. Clin Gastroenterol Hepatol. 2006;4:1491-1501.
56. van der Have M, van der Aalst KS, Kaptein AA, et al. Determinants of health-related quality of life in Crohn's disease: a systematic review and meta-Analysis. J Crohns Colitis. 2013.
57. Saibeni S, Cortinovis I, Beretta L, et al. Gender and disease activity influence health-related quality of life in inflammatory bowel diseases. Hepatogastroenterology. 2005;52:509-515.
58. Janke KH, Klump B, Gregor M, et al. Determinants of life satisfaction in inflammatory bowel disease. Inflamm Bowel Dis. 2005;11:272-286.
59. Gibson PR, Weston AR, Shann A, et al. Relationship between disease severity, quality of life and health-care resource use in a cross-section of Australian patients with Crohn's disease. J Gastroenterol Hepatol. 2007; 22:1306-1312.
60. Cohen RD. The quality of life in patients with Crohn's disease. Aliment Pharmacol Ther. 2002;16:1603-1609.
61. Gazzard BG. The quality of life in Crohn's disease. Gut. 1987;28: 378-381.
62. Ng SC, Plamondon S, Gupta A, et al. Prospective assessment of the effect on quality of life of anti-Tumour necrosis factor therapy for perineal Crohn's fistulas. Aliment Pharmacol Ther. 2009;30:757-766.
63. Iglesias-Rey M, Barreiro-de Acosta M, Caamano-Isorna F, et al. Psychological factors are associated with changes in the health-related quality of life in inflammatory bowel disease. Inflamm Bowel Dis. 2013.
64. Farrokhyar F, Marshall JK, Easterbrook B, et al. Functional gastrointestinal disorders and mood disorders in patients with inactive inflammatory bowel disease: prevalence and impact on health. Inflamm Bowel Dis. 2006;12:38-46.
65. Faust AH, Halpern LF, Danoff-Burg S, et al. Psychosocial factors contributing to inflammatory bowel disease activity and health-related quality of life. Gastroenterol Hepatol (N Y). 2012;8:173-181.
66. Walker JR, Ediger JP, Graff LA, et al. The Manitoba IBD cohort study: a population-based study of the prevalence of lifetime and 12-month anxiety and mood disorders. Am J Gastroenterol. 2008;103:1989-1997.
67. Sewitch MJ, Abrahamowicz M, Bitton A, et al. Psychological distress, social support, and disease activity in patients with inflammatory bowel disease. Am J Gastroenterol. 2001;96:1470-1479.
68. Mussell M, Bocker U, Nagel N, et al. Predictors of disease-related concerns and other aspects of health-related quality of life in outpatients with inflammatory bowel disease. Eur J Gastroenterol Hepatol. 2004;16:1273-1280.
69. Serrano J, Plaza V, Sureda B, et al. Alexithymia: a relevant psychological variable in near-fatal asthma. Eur Respir J. 2006;28:296-302.
70. Porcelli P, Leoci C, Guerra V, et al. A longitudinal study of alexithymia and psychological distress in inflammatory bowel disease. J Psychosom Res. 1996;41:569-573.
71. Porcelli P, Zaka S, Leoci C, et al. Alexithymia in inflammatory bowel disease. A case-control study. Psychother Psychosom. 1995;64:49-53.
72. Trachter AB, Rogers AI, Leiblum SR. Inflammatory bowel disease in women: impact on relationship and sexual health. Inflamm Bowel Dis. 2002;8:413-421.
73. Cottone M, Rosselli M, Orlando A, et al. Smoking habits and recurrence in Crohn's disease. Gastroenterology. 1994;106:643-648.
74. Duffy LC, Zielezny MA, Marshall JR, et al. Cigarette smoking and risk of clinical relapse in patients with Crohn's disease. Am J Prev Med. 1990;6:161-166.
75. Lindberg E, Jarnerot G, Huitfeldt B. Smoking in Crohn's disease: effect on localisation and clinical course. Gut. 1992;33:779-782.
76. von Roon AC, Karamountzos L, Purkayastha S, et al. Diagnostic precision of fecal calprotectin for inflammatory bowel disease and colorectal malignancy. Am J Gastroenterol. 2007;102:803-813.
77. Hamon JF, Beaugerie L, Parc R, et al. Care patterns and resumption of social and occupational activities after exeresis surgery in Crohn's disease. Study of 58 patients [in French]. Ann Gastroenterol Hepatol (Paris). 1995;31:215-220.
78. Scarpa M, Ruffolo C, Bassi D, et al. Intestinal surgery for Crohn's disease: predictors of recovery, quality of life, and costs. J Gastrointest Surg. 2009;13:2128-2135.
79. Naliboff BD, Kim SE, Bolus R, et al. Gastrointestinal and psychological mediators of health-related quality of life in IBS and IBD: a structural equation modeling analysis. Am J Gastroenterol. 2012; 107:451-459.
80. Guthrie E, Jackson J, Shaffer J, et al. Psychological disorder and severity of inflammatory bowel disease predict health-related quality of life in ulcerative colitis and Crohn's disease. Am J Gastroenterol. 2002;97:1994-1999.
81. Norton C, Dibley LB, Bassett P. Faecal incontinence in inflammatory bowel disease: associations and effect on quality of life. J Crohns Colitis. 2013;7:e302-e311.
82. Casellas F, Vivancos JL, Sampedro M, et al. Relevance of the phenotypic characteristics of Crohn's disease in patient perception of healthrelated quality of life. Am J Gastroenterol. 2005;100:2737-2742.
83. Kiran RP, Delaney CP, Senagore AJ, et al. Prospective assessment of cleveland global quality of life (CGQL) as a novel marker of quality of life and disease activity in Crohn's disease. Am J Gastroenterol. 2003; 98:1783-1789.
84. Mahadev S, Young JM, Selby W, et al. Quality of life in perianal Crohn's disease: what do patients consider important?. Dis Colon Rectum. 2011;54:579-585.
85. Mahadev S, Young JM, Selby W, et al. Self-reported depressive symptoms and suicidal feelings in perianal Crohn's disease. Colorectal Dis. 2012;14:331-335.
86. Lewis MC. Attributions and inflammatory bowel disease: patients' perceptions of illness causes and the effects of these perceptions on relationships. AARN News Lett. 1988;44:16-17.
87. Gomez-Gil E, Vidal A, Panes J, et al. Relationship between patient's subjective stress perception and the course of inflammatory bowel disease [in Spanish]. Gastroenterol Hepatol. 2003;26:411-416.
88. Robertson DA, Ray J, Diamond I, et al. Personality profile and affective state of patients with inflammatory bowel disease. Gut. 1989;30:623-626.
89. Bernstein CN, Singh S, Graff LA, et al. A prospective population-based study of triggers of symptomatic flares in IBD. Am J Gastroenterol. 2010;105:1994-2002.
90. Mittermaier C, Dejaco C, Waldhoer T, et al. Impact of depressive mood on relapse in patients with inflammatory bowel disease: a prospective 18-month follow-up study. Psychosom Med. 2004;66:79-84.
91. Hashimoto H, Iwao Y, Hibi T, et al. A model of quality of life in the patients with Crohn's disease [in Japanese]. Nihon Shokakibyo Gakkai Zasshi. 1999;96:1258-1265.
92. Oliveira S, Zaltman C, Elia C, et al. Quality-of-life measurement in patients with inflammatory bowel disease receiving social support. Inflamm Bowel Dis. 2007;13:470-474.
93. Gazzard BG, Price HL, Libby GW, et al. The social toll of Crohn's disease. Br Med J. 1978;2:1117-1119.
94. Iglesias-Rey M, Barreiro-de Acosta M, Caamano-Isorna F, et al. Influence of alexithymia on health-related quality of life in inflammatory bowel disease: are there any related factors?. Scand J Gastroenterol. 2012;47:445-453.
95. Timmer A, Preiss JC, Motschall E, et al. Psychological interventions for treatment of inflammatory bowel disease. Cochrane Database Syst Rev. 2011:CD006913.
96. Boye B, Lundin KE, Jantschek G, et al. INSPIRE study: does stress management improve the course of inflammatory bowel disease and disease-specific quality of life in distressed patients with ulcerative colitis or Crohn's disease?. A randomized controlled trial. Inflamm Bowel Dis. 2011;17:1863-1873.
97. Jantschek G, Zeitz M, Pritsch M, et al. Effect of psychotherapy on the course of Crohn's disease. Results of the German prospective multicenter psychotherapy treatment study on Crohn's disease. German Study Group on Psychosocial Intervention in Crohn's Disease. Scand J Gastroenterol. 1998;33:1289-1296.
98. Singleton JW, Law DH, Kelley ML Jr, et al. National Cooperative Crohn's Disease Study: adverse reactions to study drugs. Gastroenterology. 1979;77:870-882.
99. Greenberg GR, Feagan BG, Martin F, et al. Oral budesonide for active Crohn's disease. Canadian inflammatory bowel disease study group. N Engl J Med. 1994;331:836-841.
100. Suzuki Y, Motoya S, Takazoe M, et al. Efficacy and tolerability of oral budesonide in Japanese patients with active Crohn's disease: a multicentre, double-blind, randomized, parallel-group Phase II study. J Crohns Colitis. 2013;7:239-247.
101. Irvine EJ, Greenberg GR, Feagan BG, et al. Quality of life rapidly improves with budesonide therapy for active Crohn's disease. Canadian Inflammatory Bowel Disease Study Group. Inflamm Bowel Dis. 2000;6:181-187.
102. Thomsen OO, Cortot A, Jewell D, et al. A comparison of budesonide and mesalamine for active Crohn's disease. International Budesonide-Mesalamine Study Group. N Engl J Med. 1998;339:370-374.
103. Singleton JW, Hanauer SB, Gitnick GL, et al. Mesalamine capsules for the treatment of active Crohn's disease: results of a 16-week trial. Pentasa Crohn's Disease Study Group. Gastroenterology. 1993;104:1293-1301.
104. Singleton JW, Hanauer S, Robinson M. Quality-of-life results of doubleblind, placebo-controlled trial of mesalamine in patients with Crohn's disease. Dig Dis Sci. 1995;40:931-935.
105. Candy S, Wright J, Gerber M, et al. A controlled double blind study of azathioprine in the management of Crohn's disease. Gut. 1995;37:674-678.
106. Present DH, Meltzer SJ, Krumholz MP, et al. 6-Mercaptopurine in the management of inflammatory bowel disease: short-And long-Term toxicity. Ann Intern Med. 1989;111:641-649.
107. D'Haens GR, Vermeire S, Van Assche G, et al. Therapy of metronidazole with azathioprine to prevent postoperative recurrence of Crohn's disease: a controlled randomized trial. Gastroenterology. 2008;135:1123-1129.
108. Pearson DC, May GR, Fick GH, et al. Azathioprine and 6-mercaptopurine in Crohn disease. A meta-Analysis. Ann Intern Med. 1995;123:132-142.
109. Willoughby JM, Beckett J, Kumar PJ, et al. Controlled trial of azathioprine in Crohn's disease. Lancet. 1971;2:944-947.
110. Bernklev T, Jahnsen J, Schulz T, et al. Course of disease, drug treatment and health-related quality of life in patients with inflammatory bowel disease 5 years after initial diagnosis. Eur J Gastroenterol Hepatol. 2005;17:1037-1045.
111. Lewis JD, Schwartz JS, Lichtenstein GR. Azathioprine for maintenance of remission in Crohn's disease: benefits outweigh the risk of lymphoma. Gastroenterology. 2000;118:1018-1024.
112. Feagan BG, Coteur G, Tan S, et al. Clinically meaningful improvement in health-related quality of life in a randomized controlled trial of certolizumab pegol maintenance therapy for Crohn's disease. Am J Gastroenterol. 2009; 104:1976-1983.
113. Feagan BG, Yan S, Bala M, et al. The effects of infliximab maintenance therapy on health-related quality of life. Am J Gastroenterol. 2003;98: 2232-2238.
114. Targan SR, Hanauer SB, van Deventer SJ, et al. A short-Term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med. 1997;337:1029-1035.
115. Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med. 2010;362: 1383-1395.
116. Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology. 2007;132:52-65.
117. Loftus EV, Feagan BG, Colombel JF, et al. Effects of adalimumab maintenance therapy on health-related quality of life of patients with Crohn's disease: patient-reported outcomes of the CHARM trial. Am J Gastroenterol. 2008;103:3132-3141.
118. Gregor JC, McDonald JW, Klar N, et al. An evaluation of utility measurement in Crohn's disease. Inflamm Bowel Dis. 1997;3:265-276.
119. Irvine EJ, Feagan B, Rochon J, et al. Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Canadian Crohn's Relapse Prevention Trial Study Group. Gastroenterology. 1994;106:287-296.
120. Ghosh S, Goldin E, Gordon FH, et al. Natalizumab for active Crohn's disease. N Engl J Med. 2003;348:24-32.
121. Gordon FH, Lai CW, Hamilton MI, et al. A randomized placebocontrolled trial of a humanized monoclonal antibody to alpha4 integrin in active Crohn's disease. Gastroenterology. 2001;121:268-274.
122. Targan SR, Feagan BG, Fedorak RN, et al. Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial. Gastroenterology. 2007;132:1672-1683.
123. Sandborn WJ, Feagan BG, Rutgeerts P, et al. Vedolizumab as induction and maintenance therapy for Crohn's disease. N Engl J Med. 2013;369: 711-721.
124. Caprilli R, Gassull MA, Escher JC, et al. European evidence based consensus on the diagnosis and management of Crohn's disease: special situations. Gut. 2006;55(suppl 1):i36-i58.
125. De Dombal FT, Burton I, Goligher JC. The early and late results of surgical treatment for Crohn's disease. Br J Surg. 1971;58:805-816.
126. Haapamaki J, Turunen U, Roine RP, et al. Finnish patients with inflammatory bowel disease have fewer symptoms and are more satisfied with their treatment than patients in the previous European survey. Scand J Gastroenterol. 2008;43:821-830.
127. Haapamaki J, Turunen U, Roine RP, et al. Impact of demographic factors, medication and symptoms on disease-specific quality of life in inflammatory bowel disease. Qual Life Res. 2009;18:961-969.
128. Moskovitz DN, Maunder RG, Cohen Z, et al. Coping behavior and social support contribute independently to quality of life after surgery for inflammatory bowel disease. Dis Colon Rectum. 2000;43:517-521.
129. Bullen TL, Sharpe L, Lawsin C, et al. Body image as a predictor of psychopathology in surgical patients with colorectal disease. J Psychosom Res. 2012;73:459-463.
130. Siassi M, Weiss M, Hohenberger W, et al. Personality rather than clinical variables determines quality of life after major colorectal surgery. Dis Colon Rectum. 2009;52:662-668.
131. Eshuis EJ, Bemelman WA, van Bodegraven AA, et al. Laparoscopic ileocolic resection versus infliximab treatment of distal ileitis in Crohn's disease: a randomized multicenter trial (LIR!C-Trial). BMC Surg. 2008;8:15.